Abstracts Book - IMRC 2018

• SA6-P148
EVALUATION OF THE CURCUMIN-LOADED MUCOADHESIVE
LIQUID CRYSTALLINE SYSTEM FOR THE TREATMENT OF
VULVOVAGINAL CANDIDIASIS
Marlus Chorilli 1 , Camila Fernanda Rodero 1 , María Soledad Miró 2 , Claudia Elena Sotomayor 2 ,
Taís Maria Bauab 3
1
Universidade Estadual Paulista, Drugs and Medicines, Brazil. 2 Universidad Nacional de
Córdoba, Clinical Biochemistry, Argentina. 3 Universidade Estadual Paulista, Biological Scineces,
Brazil.
The incorporation of drugs into mucoadhesive liquid-crystalline systems (MLCS)
for vaginal administration can be an interesting strategy in order to potentiate
the action of the drug, as well as to obtain a longer permanance of the
formulation at the site of avoiding the process of the first-pass effect caused by
administration in the conventional route. The objective of this work was
to evaluate the MLCS loaded with curcumin for the treatment of vulvovaginal
candidiasis (VC). Phase diagram with different proportions of oleic acid and
ergosterol 5: 1 in oil phase (FO), Procetyl ® AWS as surfactant (T) and polymer
dispersion of chitosan 1% as aqueous phase (FA) were obtained. The F13-CUR
point containing 30% FO, 40% T, 30% FA and curcumin was selected, since better
results were verified in the in vitro tests. In vivo occurred in female mice (C57BL
/ 6), 8 to 10 weeks, weighing 20-25 g. They received 0.1 mL of estradiol solution
twice weekly (-5 and -2) and on day zero were infected with 20 μL of a suspension
of Candida (5 x 10 6 CFU). On days two and four they received a new dose of
estradiol to maintain the pseudo-estrus phase and vaginal lavages were
performed with PBS (240 μL) for microscopic analysis and plated on Sabouraud
Dextrose + chloramphenicol agar to verify yeast growth and treatments were
performed (12 in 12 hours for 8 days) every other day. The assay involved five
experimental groups containing four animals each, group 1 negative control
(infected and untreated), group 2 positive control of estradiol (uninfected),
group 3 treated with F13-CUR (treatment 1), group 4 treated with F13-Fluco
(treatment 2), group 5 and 6 controls of free CUR and free formulation,
respectively. In the in vivo test for treatment of vulvovaginal candidiasis the F13-
CUR formulation was able to cure two animals on the fourth day and the fungal
load decreased until the eighth day of treatment. What was not observed for
group 4 that were treated with the fluconazole-loaded formulation (F13-Fluco),
only on the sixth day observed a trend of inhibition of fungal load. Thus, there
was no decrease in the controls of groups 5 and 6, suggesting that no